medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 2

<< Back Next >>

Rev Invest Clin 2005; 57 (2)

Chronic complications in cardiac transplantation. Clinical implications and future strategies

Magaña SJA, Argüero SR

Language: Spanish
References: 31
Page: 338-343
PDF size: 61.86 Kb.


ABSTRACT

Chronic complications are situations which limit the long-term utility of cardiac transplantation. The allograft vasculopathy is the most important cause of death at 5 years alter transplantation. Another conditions are systemic arterial hypertension, nephropathies, diabetes mellitus, dyslipidemies and malignant neoplasies. The present manuscript summarizes the characteristics, clinical presentation and therapeutic strategies for this conditions.


REFERENCES

  1. Heart disease and stroke statistics. 2004 Update. American Heart Association. www.aha.org

  2. Alonso Pulpón L, Almenar L, Crespo MG, Silva L, Segovia J, Manito N, Cuenca JJ, Juffé A, Vallés F. Guías de actuación clínica de la Sociedad Española de Cardiología. Trasplante cardiaco y de corazón-pulmones. Rev Esp Cardiol 1999; 52(10): 821-39.

  3. Grady KL, Jalowiec A, White Williams C. Predictors of quality of life in patients at one year alter heart transplantation. J Heart Lung Transplant 1999; 18: 202-10.

  4. Hunt SA. Current status of cardiac transplantation. JAMA 1998; 280: 1692-8.

  5. Hertz MI, Mohacsi PJ, Taylor DO, Trulock EP, Boucek MM, Deng MC, et al. The registry of the International Society for Heart and Lung Transplantation: introduction to the Twentieth Annual reports-2003. J Heart Lung Transplant 2003; 22: 610-15.

  6. Billingham ME. Histopathology of grafo coronary disease. J Heart Lung Transplant 1992; 11(Suppl.): S38-S44.

  7. Pérez Villa F, Roig E, Ferrer E, Cuppoletti A, Llancaqueo A, Jiménez W, Sanz G. Activación neurohormonal en la insuficiencia cardiaca congestiva: ¿se normaliza después del trasplante cardíaco? Rev Esp Cardiol 2004; 57(8): 725-31.

  8. Hollenberg SM, Lloyd WK, Parrillo JE, Scherer M, Burns D, Tamburro P, et al. Coronary endotelial dysfunction alter heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104: 3091-6.

  9. Richter M, Richter H, Olbrich H, Mohr F. Two good reasons for an angiotensin-II type 1 receptor blockade with losartan alter cardiac transplantation: reduction of incidence and severity of transplant vasculopathy. Transpl Int 2003; 16: 26-32.

  10. Valentine H, Rickenbaker P, Kemna M, et al. Metabolic abnormalities characteristics of dysmetabolic syndrome predict the development of transplant coronary artery disease. Circulation 2001; 103: 2144-52.

  11. Nahlawi M, Seshadri N, Boparai N, et al. Usefulnes of plasma vitamin B6, B12, folate, homocysteine and creatinine in predicting outcomes in heart transplant recipients. Am J Cardiol 2002; 89: 834-7.

  12. Constanzo MR. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992; 11: 90-104.

  13. Mehra MR, Prasad A, Uber PA, et al. The impact of explosive brain death on the genesis of cardiac allograft vasculopathy: an intravascular ultrasound study. J Heart Lung Transplant 2000; 19: 522-8.

  14. Vasilescu ER, Ho EK, De la Torre L, et al. Anti HLA antibodies in heart transplantation. Traspl Immunol 2004; 12: 177-83.

  15. Rusell PS, Chase CM, Win HJ, et al. Coronary atherosclerosis in Mouse hearts I: time course and immunogenetic and immunopathological considerations. J Am Pathol 1994; 144: 260-9.

  16. Grattan MT, Moreno CE, Stames VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-6.

  17. Stara RP, Mcginn AL, Wilson RF. Chest pain in cardiac transplant recipients. Evidence of sensory reinnervation alter cardiac transplantation. N Engl J Med 1991; 324: 1791-4.

  18. Smart FW, Ballantyne CM, Cocanougher B, et al. Insensivity of non invasive tests to detect coronary artery vasculopathy after Heart transplant. 1991; 67: 243-7.

  19. Kapadia SR, Nissen SE, Tuzcu EM. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr Opin Cardiol 1999; 14: 140-50.

  20. Flugfelder PW, Boghner DR, Rudas L, et al. Enhanced detection of cardiac allograft arterial disease with intracoronary ultrasonographic imaging. Am Heart J 1993; 125: 1583-91.

  21. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.

  22. Millar LW, Wolford T, McBride LR, et al. Succesful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 1992; 11: 431-4.

  23. Braith R, Mills R, Wilcox C, Davis W, Word C. Breakdown of blood pressure and body fluid homeostasis in heart transplant recipients. J Am Coll Cardiol 1996; 27: 375-83.

  24. Van Gelder T, Balk AH, Sietze R, Hesse C, Mochtar B, Weimer W. Survival of heart transplant recipients with cyclosporine indiced renal insuficciency. Transplant Proc 1998; 30: 1122-3.

  25. Depczynski B, Daly B, Campbell LV, et al. Predicting the ocurrente of diabetes mellitus in recipients of heart transplants. Diabet Med 2000; 17: 15-19.

  26. Mihalov ML, Gattuso P, Abraham K, et al. Incidente of post-transplant malignancy among 674 solid organ transplant recipients at a single center. Clin Transplant 1996; 10: 248-55.

  27. Massy ZA. Hyperlipidemia and cardiac disease alter organ transplantation. Transplantation 2001; 21: 68.

  28. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999; 34: 890-911.

  29. Butler J, Khadim G, Paul KM, Davis SF, Kronenberg MW, Chomsky DB, et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol 2004; 43: 787-93.

  30. Young JB, Abraham WT, Smith AL, et al. Safety and efficacy of combined cardiac resynchronization therapy and implantable cardioversion defibrillation in patients with advanced chronic heart failure, the multicenter insync ICD randomized clinical evaluation (MIRACLE ICD) trial. JAMA 2003; 289: 2685-94.

  31. Melo LG, Pachori AS, Kong D, Gnecchi M, Wang K, Pratt RE, Dzau VJ. Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: Reasons for cautious optimism. Circulation 2004; 109: 2386-93.




2020     |     www.medigraphic.com